+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antidepressants - Global Strategic Business Report

  • ID: 338526
  • Report
  • Region: Global
  • 408 Pages
  • Global Industry Analysts, Inc
1 of 3

FEATURED COMPANIES

  • AstraZeneca Plc (UK)
  • Eli Lilly and Co. (USA)
  • Forest Laboratories (USA)
  • GlaxoSmithKline Plc (UK)
  • H. Lundbeck A/S (Denmark)
  • Merck & Co. (USA)
  • MORE
This report analyzes the worldwide markets for Antidepressants in Millions of US$. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Latin America. Annual forecasts are provided for each region for the period of 2000 through 2010. The report profiles 45 companies including many key and niche players worldwide such as AstraZeneca PLC, Bristol-Myers Squibb, Eli Lilly and Co., Forest Laboratories, GlaxoSmithKline PLC, H. Lundbeck A/S, Merck & Co., Novartis AG, Organon International, Inc., Pfizer, Inc., Solvay SA, and Wyeth Pharmaceuticals.

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.

For information on site licence pricing please click on "Enquire before buying"
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AstraZeneca Plc (UK)
  • Eli Lilly and Co. (USA)
  • Forest Laboratories (USA)
  • GlaxoSmithKline Plc (UK)
  • H. Lundbeck A/S (Denmark)
  • Merck & Co. (USA)
  • MORE
ANTIDEPRESSANTS

A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

II.

1. Industry Overview II-1
Market Highlights II-1
Current and Future Analysis II-1
Industry Dynamics and Changing Scenario II-2
Intense Competition in the Antidepressants Marketplace II-2
Global Antidepressants Market (2004): Major Products in the
Pipeline II-3
Table 1: Leading Brands in the Global Antidepressants Market
(2001 & 2002): Sales in US$ Million for Seroxat/Paxil,
Zoloft, Effexor, Cipramil/ Celexa, Wellbutrin, Prozac,
Remeron, Fluoxetine Par, Serzone, and Fluoxetine Barr
(include corresponding Graphs/Chart) II-4

Table 2: Leading Drugs in the Global Antidepressants Market
(2003): Sales in US$ Million for Seroxat, Zoloft, Effexor,
Cipramil/ Celexa, Wellbutrin, Cipralex/ Lexapro, Prozac,
and Remeron (include corresponding Graphs/Chart) II-5
SSRI/SNRI Brands in the Global Antidepressants Market
(2002-2006): Sales in US$ Million by Geographic Region for
Cipralex/Lexapro, Effexor, Cipramil/ Celexa, Paxil,
Zoloft, and Cymbalta II-6
SSRIs Garnering Major Share of the Market II-7
Table 3: Leading Brands in the Global SSRI Antidepressants
Market (2003): Percentage Breakdown of Value Sales for
Zoloft, Paxil and Paxil CR, Generic Fluoxetine, Celexa,
Lexapro, Prozac, Prozac Weekly, and Others (include
corresponding Graphs/Chart) II-7
Emerging Antidepressant Classes Pose Threat to SSRI II-8
Market Snapshots II-8

2. Market Trends & Issues II-9
New Drugs Making Way into the Market II-9
Prozac Patent Expiry Opens Door for Generic Versions II-9
Generic Antidepressants to Hit Market Soon II-9
TCA Antidepressants Still in Use II-10
Improved Marketing Spurs Growth II-10
Westerners Fight Depression Blues
Americans Top the List II-10
Antidepressants High in Demand but Fail to Satisfy Consumers II-10
No One is Immune: Not Even Animals! II-11
Patent Expiry Disturbs Antidepressants Producers II-11
Unlicensed Antidepressants Pose Danger to Youth Safety II-11
Global Antidepressants Market (2003): Regulations Governing
Select Antidepressants Use in Children II-12
Growing Safety Concerns
Antidepressants Under Fire II-12
The Debate Flares II-12
Are Antidepressants Totally Safe? A Moot but Important Question II-12
Manufacturers Vociferous in their Protests II-13
No Satisfactory Answers Yet
The Wait Grows Longer II-13
Global Antidepressants Market: Drug Regulation for Kids in
Britain and the United States II-13

3. Depression: A Mental Review II-14
What is depression? II-14
Symptoms of Depression II-14
Causes of Depression II-14
Types of Depression and Related Disorders II-15
Major Depressive Disorders (Major Depression) II-15
Dysthymic Disorder (Minor Depression) II-15
Bipolar Disorder II-15
Related Disorder Types II-15
Seasonal Affective Disorder II-16
Premenstrual Dysphoric Disorder (PMDD) II-16
Anxiety Disorders II-16
Obsessive Compulsive Disorder II-16
Generalized Anxiety Disorder II-16
Panic Disorder II-16
Treatment of Depression II-16
Options Available in Depression Treatment II-17
Psychotherapy or Psychiatric Consultation II-17
Pharmacotherapy II-17
Combination of Psychotherapy and Pharmacotherapy II-17
Herbal and Nutritional Treatment II-17
Exercise II-17
How Can Depression Treatment become More Effective? II-17
Global Antidepressants Market: Favorable Drugs Under
Specific Conditions II-18
Global Antidepressants Market: Unfavorable Drugs Under
Specific Conditions II-18
Treatment-Resistant Depression (TRD) II-19
Optimizing the Dosage II-19
Switching of Medications II-19
Combination therapy II-19
Augmentation Therapy II-19
Electroconvulsive Therapy II-19
Facts and Figures on Depression II-20
Table 4: Global Antidepressants Market (2004): Percentage
Breakdown of Prevalence Rate by Disorder Type
Depression,
Anxiety, Obsessive Compulsive Disorder, Sleep Disorder,
Panic Disorder, Phobias, and Others (include corresponding
Graphs/Chart) II-20
Depression Hits the Elderly Hard II-20
Men Vs Women
Who is More Depression Prone? II-21
Depression and Smoking
Interlinked to One Another II-22

4. Product Analysis II-23
What are Antidepressants? A Clear Understanding II-23
Global Antidepressants Market (2004): Select Brands and their
Manufacturers II-23
Application Areas II-23
Select Antidepressants and their Applications II-24
Types of Antidepressants II-24
Tricyclic Antidepressants (TCAs) II-25
Global Antidepressants Market: TCA Brands and Dosage Types

Starting Dosage and Normal Dosage II-25
Global Antidepressants Market: TCAs and their Side Effects II-26
Monamine Oxidase Inhibitors (MAOIs) II-26
Global Antidepressants Market: MAOI Brands and Dosage Types

Starting Dosage and Normal Dosage II-26
Side Effects of Different MAOIs
Tranylcypromine

Isocarboxazid and Phenelzine II-27
Selective Serotonin Reuptake Inhibitors (SSRIs) II-27
Global Antidepressants Market: SSRIs Brands and Related
Dosage
Starting Dosage and Normal Dosage II-27
Pharmacology II-27
FDA Approval II-28
Fluoxetine (Proxac) II-28
Citalopram II-28
Fluvoxamine (Luvox) II-28
Paroxetine II-29
Sertraline (Zoloft) II-29
Escitalopram II-29
Side Effects II-29
Global Antidepressants Market: Different SSRI Drugs and
their Side Effects II-30
Applications II-30
Global Antidepressants Market: SSRIs’ Off-Label
Application Areas and Medication II-30
New Generation Antidepressants II-31
Dopamine-Reuptake Blocking Compounds II-31
Bupropion II-31
Serotonin and Noradrenaline Reuptake Inhibitors II-31
Venlafaxine II-31
5HT2 Receptor Antagonist Properties II-32
Nefazodone II-32
Trazodone II-32
Noradrenergic Antagonist II-32
Mirtazapine II-32
Global Antidepressants Market: New Generation Drugs and
Dosage Types
Starting Dosage and Normal Dosage II-33
Global Antidepressants Market: New Generation
Antidepressants and their Side Effects II-33
Global Antidepressants Market: Major Drugs by Class -
SSRI, SNRI, MAOI, and NaSSA II-34

5. Antidepressants: An In-Depth Analysis II-35
Tracing the Line of History II-35
Antidepressants, a Mere Accidental Discovery II-35
Limited Choices and High Risk Rates II-35
Better Alternatives and Wider Choice
The New Mantra II-35
Global Antidepressants Market: Launch of Drug Types
TCAs,
MAOI, SSRI, and New Generation Variants by Original
Version, Secondary Version, and Generic Version II-36
Adverse Effects of Antidepressants and their Management II-37
Sedation II-37
Orthostatic Hypotension II-37
Insomnia II-37
Anticholinergic Effects II-38
Weight Gain/Loss II-38
Sexual Dysfunction II-38
Side Effects Associated with Overdose II-38
Choosing an Antidepressant II-39
Table 5: Global Antidepressants Market: Percentage Breakdown
of Volume Drug Consumption by Disorder Type
Depression,
Generalized Anxiety Disorder, Post Traumatic Stress Disorder,
Panic Disorder and Others (include corresponding Graphs/
Chart) II-39
Switching Antidepressants II-40
Do Antidepressants Treat Depression Completely? II-40
Are Antidepressants Addictive? II-41
Global Antidepressants Market: Withdrawal Symptoms by Drug
Types
TCAs and SSRIs II-41
Disorders and Antidepressants II-42
Bipolar Disorder II-42
Anxiety Disorder II-42
Panic Disorder II-42
Antidepressants Used for Treatment of Panic Disorders,
their Efficacy/Recommendations, and Side Effects II-43
A Note of Caution for Panic Patients Using Antidepressants II-43
Generalized Anxiety Disorder II-43
SNRI II-44
SSRI II-44
TCAs II-44
Antidepressants Used for Treatment of Anxiety Disorders II-44
Antidepressants: Causes For and Against II-45
Cause for Antidepressants: II-45
Antidepressants Effective in Curing Premenstrual Dysphoric
Disorder II-45
Antidepressants Offer Solution for Itching and Scratching II-46
Antidepressants Offer Hope for Autistic Children II-46
Antidepressants Minimize Hot Flushes and Night Sweats II-46
Antidepressants’ Positive Effect on the Brain II-47
Longer Duration Antidepressants Treatment Prevents Relapse II-47
Antidepressants
A New Option for Sleep Apnea II-47
SSRI Antidepressants May Prove Helpful in Cancer Treatment II-48
Antidepressants Relaxes Tremors II-48
Lesser Fear of Breast Cancer with Antidepressants II-48
Antidepressants for Reducing Chronic Back Pain II-48
Causes Against Antidepressants II-48
Greater Heart at Risk with Antidepressants II-48
Antidepressants Dissipates Sexual Drive II-49
Hip Fractures Troubles Aged Patients II-49
Antidepressants can be a Deadly Prescription for Kids II-50
Dental Problems with Antidepressants II-50
Facts/Myths About Antidepressants II-50
Are Pregnant Women at Risk from Antidepressants? II-50
Is Breast Feeding Safe While on Antidepressants? II-51
Homeopathic Treatment Versus Antidepressants Treatment -
Which is Better? II-51
Recent Findings on Antidepressants II-52

6. Technological Developments II-53
Monitoring Technology Foresees Antidepressants Effect II-53
Vagus Nerve Stimulation
Device for Treating Depression II-53
Global Antidepressants Market: FDA Approvals (2002-2004) II-53

7. Product Introductions/Innovations II-54
GlaxoSmithKline Re-Introduces Paxil CR in US Market II-54
Ratiopharm Launches Ratio-Paroxetine in Canada II-54
Organon Introduces Zispin SolTab II-54
Apotex Releases Generic Version of Paxil II-54
GlaxoSmithKline Launches Paxil CR II-54
Lundbeck Launches Lexapro II-55

8. Recent Industry Activity II-56
Pfizer Acquires Esperion II-56
Organon in Marketing Agreement with STADA II-56
Andrx Signs Marketing Agreement with Impax and Teva II-56
GlaxoSmithKline Collaborates with NeuroSearch II-56
Lundbeck in Marketing Accord with Janssen-Cilag II-56
Lundbeck Allies with Abbott Laboratories II-57
Myriad Signs an Agreement with Abbott Laboratories II-57
Recordati Obtains Marketing Rights from H Lundbeck II-57

9. Focus on Select Global Players II-58
AstraZeneca Plc (UK) II-58
Bristol-Myers Squibb (USA) II-58
Eli Lilly and Co. (USA) II-58
Forest Laboratories (USA) II-59
GlaxoSmithKline Plc (UK) II-59
H. Lundbeck A/S (Denmark) II-60
Merck & Co. (USA) II-60
Novartis AG (Switzerland) II-60
Organon International, Inc. (USA) II-60
Pfizer, Inc. (USA) II-61
Solvay SA (Brussels) II-61
Wyeth Pharmaceuticals (USA) II-61

10. Global Market Perspective II-63
Table 6: World Recent Past, Current & Future Analysis for
Antidepressants by Geographic Region
USA, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), and Latin America
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (include
corresponding Graphs/Chart) II-63

Table 7: World 10-Year Perspective for Antidepressants by
Geographic Region
Percentage Breakdown of Dollar Sales for
USA, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
and Latin America Markets for Years 2000, 2005 & 2010
(include corresponding Graphs/Chart) II-64

III. MARKET

1. The United States III-1
A.Market Analysis III-1
Current and Future Analysis III-1
Market Overview III-1
Antidepressants Usage in the United States III-1
US Antidepressants Market: Drug Usage III-2
Competitive Scenario III-2
Table 8:Leading Players in the US Antidepressants Market (
2004 & 2005(E)): Percentage Breakdown of Value Sales for
Forest Labs, GlaxoSmithKline, Pfizer, Wyeth, Eli Lilly and
Others (include corresponding Graphs/Chart) III-2

Table 9: Leading Players in the US SSRI/SNRI Market (2004 &
2005(E)): Percentage Breakdown of Value Sales for Forest
Labs, Pfizer, Wyeth, GlaxoSmithKline, Eli Lilly and Others
(include corresponding Graphs/Chart) III-3
Trends and Issues III-3
Are Americans Getting Too Depressed? III-3
New Drugs Set to Conquer the Market III-4
Table 10: Leading SSRI/ SNRI Brands in the US
Antidepressants Market (2000-2005(E)): Percentage
Breakdown of Sales for Prozac, Paxil, Zoloft, Celexa,
Lexapro, Effexor and Others (include corresponding
Graphs/Chart) III-4

Table 11: US Antidepressants Market (2000-2003): Number of
SSRI/SNRI Prescriptions Dispensed in Millions (include
corresponding Graphs/Chart) III-5

Table 12: US Antidepressants Market (2000): Advertising
Expenditure in US$ Million on Select SSRIs
Celexa
(Citalopram), Prozac (Fluoxetine), Effexor XR (Venlafaxine
), Zoloft (Sertraline), Paxil (Paroxetine), and Luvox
(Fluvoxamine) (include corresponding Graphs/Chart) III-5
Depression More Common Among Gays III-5
FDA Inspects Suicidal Tendencies in Kids on Antidepressants III-6
FDA Imposes "black-box" Warning III-6
Generic Drugs Pose Competition to Branded Drugs III-7
Table 13: Leading SSRI Brands in the US Antidepressants
Market (2001): Sales in US$ Million for Zoloft, Paxil,
Prozac & Sarafem, Celexa, and Luvox (include
corresponding Graphs/Chart) III-7
Depression Drugs Being Used for Symptoms Other Than
Depression III-7
US Antidepressants Market: Drugs Approved for Different
Indications III-8
Frequent Patent Expiries
A Cause of Concern for
Manufacturers III-8
Patent Expiry of Select Antidepressant Brands in the
United States III-8
Product Launches/Developments III-9
Strategic Corporate Developments III-10
Key Players III-10
Bristol-Myers Squibb III-10
Eli Lilly and Co. III-11
Forest Laboratories III-11
Merck & Co. III-11
Organon International, Inc. III-12
Pfizer, Inc. III-12
Wyeth Pharmaceuticals III-12
B.Market Analytics III-13
Table 14: US Recent Past, Current & Future Analysis for
Antidepressants by Product Segment
SSRI, New Generation,
TCA and MAOI Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (include
corresponding Graphs/Chart) III-13

Table 15: US 10-Year Perspective for Antidepressants by
Product Segment
Percentage Breakdown of Dollar Sales for
SSRI, New Generation, TCA and MAOI for Years 2000, 2005 &
2010 (include corresponding Graphs/Chart) III-14

2. Canada III-15
A.Market Analysis III-15
Current and Future Analysis III-15
Market Overview III-15
Increasing Use of Antidepressants among Canadian Women III-15
Antidepressants Market
A Recent Past Perspective III-15
Table 16: Canadian Antidepressants Market (2001):
Percentage Breakdown of Value Sales by Class
SSRI, TCAs,
MOAI, and Others (include corresponding Graphs/Chart) III-16
Generic Serzone Recalled from Canadian Market in 2003 III-16
Warning Against Antidepressants Use in Under- 18 Age Group III-16
Product Launch III-17
B.Market Analytics III-17
Table 17: Canadian Recent Past, Current & Future Analysis
for Antidepressants: Annual Sales Figures in US$ Million
for Years 2000 through 2010 (include corresponding Graphs/
Chart) III-17

3. Japan III-18
A.Market Analysis III-18
Current and Future Analysis III-18
Recent Past Perspective III-18
Table 18: CNS Market in Japan (2001): Sales in US$ Million
by Drug Class
Antidepressants, Antiulcerants, Cholesterol
Reducers, Broad Antibiotic, Antiarrhythmic,
Antihypertensive, Narcotic painkiller, Oral Diabetes, Oral
Antihistamine, and Antiseizure (include corresponding
Graphs/Chart) III-19
Competitive Scenario III-19
Table 19: Leading Brands in the Japanese Antidepressants
Market (2001 & 2002): Percentage Breakdown of Value Sales
for Paxil, Luvox, Depromel, Ludiomil, Toledomin,
Toledomin- Jansen, Anafranil, Tetramide, and Others
(include corresponding Graphs/Chart) III-20
A Historical Perspective III-20
Antidepressants Market in Japan
Major Drug Launches the
Period 1973-2000 III-21
B.Market Analytics III-22
Table 20: Japanese Recent Past, Current & Future Analysis
for Antidepressants: Annual Sales Figures in US$ Million
for Years 2000 through 2010 (include corresponding Graphs/
Chart) III-22

4. Europe III-23
A.Market Analysis III-23
Current and Future Analysis III-23
Market Overview III-23
Table 21: Leading Players in the European Antidepressants
Market (2004 & 2005(E))
Percentage Breakdown of Value
Sales for GlaxoSmithKline, Eli Lilly, Lundbeck, Pfizer,
Wyeth and Others (include corresponding Graphs/Chart) III-24
Changes in European Patent Litigation III-24
Strategic Corporate Developments III-24
B.Market Analytics III-25
Table 22: European Recent Past, Current & Future Analysis
for Antidepressants by Geographic Region
France, Germany,
UK, Italy, Spain, and Rest of Europe Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2010 (include corresponding Graphs/Chart) III-25

Table 23: European 10-Year Perspective for Antidepressants
by Geographic Region
Percentage Breakdown of Dollar Sales
for France, Germany, UK, Italy, Spain, and Rest of Europe
Markets for Years 2000, 2005 & 2010 (include corresponding
Graphs/Chart) III-26

4a. France III-27
Market Analysis III-27
Current and Future Analysis III-27
Table 24: French Recent Past, Current & Future Analysis for
Antidepressants: Annual Sales Figures in US$ Million for
Years 2000 through 2010 (include corresponding Graphs/
Chart) III-27

4b. Germany III-28
Market Analysis III-28
Current and Future Analysis III-28
Table 25: German Recent Past, Current & Future Analysis for
Antidepressants: Annual Sales Figures in US$ Million for
Years 2000 through 2010 (include corresponding Graphs/
Chart) III-28

4c. The United Kingdom III-29
A.Market Analysis III-29
Current and Future Analysis III-29
Market Overview III-29
A Recent Past Perspective III-29
UK Bans Antidepressant Use in Children (2003) III-29
Table 26: Antidepressants Market in the UK (1993-2000):
Number of Associated Deaths in England and Wales by Drug
Class
TCAs, MAOIs, SSRIs and Others (include
corresponding Graphs/Chart) III-30
Prescriptions and Expenditure Statistics III-30
Regional Analysis
Scotland III-30
Antidepressants, a Happy Pill for Sad Scots III-30
Key Players III-31
AstraZeneca III-31
GlaxoSmithKline III-31
B.Market Analytics III-32
Table 27: UK Recent Past, Current & Future Analysis for
Antidepressants: Annual Sales Figures in US$ Million for
Years 2000 through 2010 (include corresponding Graphs/
Chart) III-32

4d. Italy III-33
Market Analysis III-33
Current and Future Analysis III-33
Table 28: Italian Recent Past, Current & Future Analysis
for Antidepressants: Annual Sales Figures in US$ Million
for Years 2000 through 2010 (include corresponding Graphs
/Chart) III-33

4e. Spain III-34
Market Analysis III-34
Current and Future Analysis III-34
Table 29: Spanish Recent Past, Current & Future Analysis
for Antidepressants: Annual Sales Figures in US$ Million
for Years 2000 through 2010 (include corresponding Graphs
/Chart) III-34

4f. Rest of Europe III-35
A.Market Analysis III-35
Current and Future Analysis III-35
Focus on Select Regional Markets III-35
Denmark III-35
Danish People Display Greater Preference for Antidepressants III-35
Finland III-35
Antidepressants Consumption Increases Among Young Adults III-35
Key Players III-35
H. Lundbeck A/S (Denmark) III-35
Novartis AG (Switzerland) III-36
Solvay SA (Brussels) III-36
B.Market Analytics III-36
Table 30: Rest of Europe Recent Past, Current & Future
Analysis for Antidepressants: Annual Sales Figures in US$
Million for Years 2000 through 2010 III-34 (include
corresponding Graphs/Chart) III-36

5. Asia-Pacific III-37
A.Market Analysis III-37
Current and Future Analysis III-37
Australia III-37
A Recent Past Market Perspective III-37
Commonly Used Antidepressants in Australia (2001) III-37
Strategic Corporate Development III-38
B.Market Analytics III-38
Table 31: Asia-Pacific Recent Past, Current & Future
Analysis for Antidepressants: Annual Sales Figures in US$
Million for Years 2000 through 2010 (include corresponding
Graphs/Chart) III-38

6. Latin America III-39
A.Market Analysis III-39
Current and Future Analysis III-39
Chile III-39
High Usage of Antidepressants among Chileans III-39
Strategic Corporate Development III-39
B.Market Analytics III-40
Table 32: Latin America Recent Past, Current & Future
Analysis for Antidepressants: Annual Sales Figures in US$
Million for Years 2000 through 2010 (include corresponding
Graphs/Chart) III-40

IV. COMPETITION

1. Abbott Laboratories (USA) IV-1
Table 33: Half Yearly Sales Analysis: 2004-2005 (H1)
(In US$ million) IV-4

Table 34: Half Yearly Sales Analysis by Segment: 2004-
2005 (H1) (In US$ million) IV-4

Table 35: Quarterly Sales Analysis: 2003-2004 (In US$
million) IV-4

Table 36: Annual Sales Analysis by Segment: 2003-2004
(In US$ million) IV-4

Table 37: Annual Sales Analysis by Geographical Region:
2003-2004 (In US$ million) IV-5
Abbott India Ltd. (India) IV-21
2. Akzo Nobel NV (The Netherlands) IV-23
Table 38: First Quarter Sales Analysis: 2004-2005 (Q1)
(In € million) IV-28

Table 39: First Quarter Sales Analysis by Segment:
2004-2005 (Q1) (In € million) IV-28

Table 40: Annual Sales Analysis: 2002-2004 (In €
million) IV-28

Table 41: Annual Sales Analysis by Segment: 2003-2004
(In € million) IV-28

Table 42: Annual Sales Analysis by Region: 2003-2004
(In € million) IV-29
Organon NV (The Netherlands) IV-35
Organon International, Inc. (USA) IV-36
Organon Laboratories Ltd. (UK) IV-41
3. Andrx Corporation (USA) IV-43
Table 43: First Quarter Sales Analysis: 2004-2005 (Q1)
(In US$ million) IV-44

Table 44: Annual Sales Analysis: 2003-2004 (In US$
million) IV-44

Table 45: Quarterly Sales Analysis: 2003-2004 (In US$
million) IV-45
4. Apotex, Inc. (Canada) IV-52
5. AstraZeneca PLC (UK) IV-54
Table 46: First Quarter Sales Analysis: 2004-2005 (Q1)
(In US$ billion) IV-56
Table 47: First Quarter Sales Analysis by Geographic
Region: 2004-2005 (Q1) (In US$ billion) IV-57
Table 48: Annual Sales Analysis: 2003-2004 (In US$
billion) IV-57

Table 49: Annual Sales Analysis by Therapy Area: 2003-
2004 (In US$ billion) IV-57

Table 50: Annual Sales Analysis by Geographic Region:
2003-2004 (In US$ billion) IV-57
Astrazeneca Pharmaceuticals LP (USA) IV-66
6. Barr Laboratories, Inc. (USA) IV-68
Table 51: Nine Months Sales Analysis: 2004-2005 (Nine
months Ended, March) (In US$ million) IV-68

Table 52: Nine Months Sales Analysis by Product: 2004-
2005 (Nine Months Ended, March) (In US$ million) IV-68

Table 53: Annual Sales Analysis: 2003-2004 (In US$
million) IV-69

Table 54: Annual Sales Analysis by Product: 2003-2004
(In US$ million) IV-69
7. Boehringer Ingelheim GmbH (Germany) IV-71
Table 55: Annual Sales Analysis: 2003-2004 (In €
million) IV-71

Table 56: Annual Sales Analysis by Product Segment:
2003-2004 (In € million) IV-71

Table 57: Annual Sales Analysis by Region: 2003-2004
(In € million) IV-72
8. Bristol-Myers Squibb Co. (USA) IV-77
Table 58: Annual Sales Analysis: 2003-2004 (In US$
billion) IV-79

Table 59: Annual Sales Analysis by Segment: 2003-2004
(In US$ billion) IV-79

Table 60: Annual Sales Analysis by Geographic Region:
2003-2004 (In US$ billion) IV-79
9. Cortex Pharmaceuticals, Inc. (USA) IV-91
10. Dr. Reddys Laboratories Ltd. (India) IV-93
Table 61: Annual Sales Analysis: 2003-2005 (In INR
million) IV-94

Table 62: Annual Sales Analysis by Product Segment:
2003-2004 (In INR million) IV-95

Table 63: Annual Sales Analysis by Geographical Region:
2003-2004 (In INR million) IV-95
11. Eli Lilly and Company (USA) IV-97
Table 64: Half Yearly Sales Analysis: 2004-2005 (H1)
(In US$ million) IV-99

Table 65: Half Yearly Sales Analysis by Segment: 2004-
2005 (H1) (In US$ million) IV-99

Table 66: Half Yearly Sales Analysis by Product: 2004-
2005 (H1) (In US$ million) IV-99

Table 67: Annual Sales Analysis: 2002-2004 (In US$
million) IV-100

Table 68: Annual Sales Analysis by Segment: 2003-2004
(In US$ million) IV-100

Table 69: Annual Sales Analysis by Product: 2003-2004
(In US$ million) IV-100

Table 70: Annual Sales Analysis by Geographical Region:
2003-2004 (In US$ million) IV-101

Table 71: Quarterly Sales Analysis: 2003-2004 (In US$
million) IV-101
Eli Lilly And Company Limited (UK) IV-107
Eli Lilly Canada, Inc. (Canada) IV-107
Lilly Deutschland GmbH (Germany) IV-108
12. Eon Labs, Inc. (USA) IV-110
Table 72: First Quarter Sales Analysis: 2004-2005 (Q1)
(In US$ million) IV-111

Table 73: Annual Sales Analysis: 2002-2004 (In US$
million) IV-111

Table 74: Quarterly Sales Analysis: 2003-2004 (In US$
million) IV-111
13. F. Hoffmann-La Roche Ltd. (Switzerland) IV-112
Table 75: Half Yearly Sales Analysis: 2004-2005 (H1)
(In CHF million) IV-113

Table 76: Annual Sales Analysis: 2003-2004 (In CHF
million) IV-113

Table 77: Annual Sales Analysis by Division: 2003-2004
(In CHF millions) IV-113
14. Forest Laboratories, Inc. (USA) IV-118
Table 78: First Quarter Sales Analysis: 2005-2006 (Q1)
(In US$ billion) IV-119

Table 79: Annual Sales Analysis: 2004-2005 (In US$
billion) IV-119

Table 80: Quarterly Sales Analysis: 2004-2005 (In US$
billion) IV-119

Table 81: Annual Sales Analysis by Geographical Region:
2004-2005 (In US$ billion) IV-120

Table 82: Quarterly Sales Analysis: 2003-2004 (In US$
billion) IV-120

Table 83: Annual Sales Analysis by Geographical Region:
2003-2004 (In US$ billion) IV-120
Forest Pharmaceuticals, Inc. (USA) IV-124
15. GlaxoSmithKline PLC (UK) IV-125
Table 84: Half Yearly Sales Analysis: 2004-2005 (H1)
(In £ million) IV-126

Table 85: Half Yearly Sales Analysis by Division: 2004
  • 2005 (H1) (In £ million) IV-126
Table 86: Annual Sales Analysis: 2003-2004 (In £
million) IV-126

Table 87: Annual Sales Analysis by Division: 2003-2004
(In £ million) IV-126
GlaxoSmithKline PLC (UK) IV-136
GlaxoSmithKline PLC (UK) IV-138
Glaxo Smithkline Canada, Inc. (Canada) IV-139
16. H. Lundbeck A/S (Denmark) IV-141
Table 88: Annual Sales Analysis: 2002-2004 (In DKK
billion) IV-142

Table 89: Annual Sales Analysis by Geographical Region:
2003-2004 (In DKK billion) IV-142
17. Impax Laboratories, Inc. (USA) IV-144
18. Johnson & Johnson (USA) IV-147
Table 90: First Quarter Sales Analysis: 2004-2005 (Q1)
(In US$ billion) IV-149

Table 91: First Quarter Sales Analysis by Segment:
2004-2005 (Q1) (In US$ billion) IV-149
Table 92: First Quarter Sales Analysis by Geographical
Region: 2004-2005 (Q1) (In US$ billion) IV-149
Table 93: Annual Sales Analysis: 2003-2004 (In US$
billion) IV-149

Table 94: Annual Sales Analysis by Segment: 2003-2004
(In US$ billion) IV-149

Table 95: Annual Sales Analysis by Geographical Region:
2003-2004 (In US$ billion) IV-150

Table 96: Annual Sales Analysis by Quarter: 2003-2004
(In US$ billion) IV-150
19. Janssen-Cilag International NV (Belgium) IV-157
20. Juvantia Pharma (Finland) IV-159
21. Meiji Seika Kaisha Ltd. (Japan) IV-160
Table 97: Annual Sales Analysis: 2003-2004 (In ¥
million) IV-160

Table 98: Annual Sales Analysis by Business Segment:
2003-2004 (In ¥ million) IV-160
22. Merck & Co., Inc. (USA) IV-162
Table 99: Annual Sales Analysis: 2003-2004 (In US$
million) IV-162

Table 100: Annual Sales Analysis by Segment: 2003-2004
(In US$ Million) IV-163

Table 101: Quarterly Sales Analysis: 2003-2004 (In US$
Million) IV-163
23. Mylan Laboratories, Inc. (USA) IV-165
Table 102: First Quarter Sales Analysis: 2005-2006 (Q1)
(In US$ million) IV-166

Table 103: Annual Sales Analysis: 2003-2005 (In US$
million) IV-166

Table 104: Annual Sales Analysis by Business Segment:
2004-2005 (In US$ million) IV-166

Table 105: Annual Sales Analysis by Product: 2004-2005
(In US$ million) IV-166

Table 106: Quarterly Sales Analysis: 2004-2005 (In US$
million) IV-167
24. Myriad Genetics, Inc. (USA) IV-170
Table 107: Annual Sales Analysis: 2003-2004 (In US$
million) IV-171

Table 108: Annual Sales Analysis by Segment: 2003-2004
(In US$ million) IV-171
25. Neurosearch A/S (Denmark) IV-173
26. Novartis AG (Switzerland) IV-175
Table 109: Half Yearly Sales Analysis: 2004-2005 (H1)
(In US$ billion) IV-178

Table 110: Annual Sales Analysis: 2002-2004 (In US$
billion) IV-179

Table 111: Annual Sales Analysis by Division: 2003-2004
(In US$ billion) IV-179

Table 112: Annual Sales Analysis by Geographical
Region: 2003-2004 (In US$ billion) IV-179

Table 113: Quarterly Sales Analysis: 2003-2004 (In US$
billion) IV-179
Sandoz, Inc. (Austria) IV-187
Sandoz Deutschland GmbH (Germany) IV-190
27. Olympian Labs (USA) IV-191
28. Orion Corporation (Finland) IV-195
Table 114: Annual Sales Analysis: 2003-2004 (In €
billion) IV-196
29. Paddock Laboratories, Inc. (USA) IV-198
30. Par Pharmaceutical, Inc. (USA) IV-202
Table 115: First Quarter Sales Analysis: 2004-2005 (Q1)
(In US$ million) IV-202

Table 116: Annual Sales Analysis: 2003-2004 (In US$
million) IV-203

Table 117: Annual Sales Analysis by Quarter: 2003-2004
(In US$ million) IV-203
31. Pfizer, Inc. (USA) IV-205
Table 118: Half Yearly Sales Analysis: 2004-2005 (H1)
(In US$ billion) IV-207

Table 119: Annual Sales Analysis: 2003-2004 (In US$
billion) IV-207

Table 120: Annual Sales Analysis by Business Segment:
2003-2004 (In US$ billion) IV-207

Table 121: Annual Sales Analysis by Geographic Region:
2003-2004 (In US$ billion) IV-207
Pfizer Australia Pty., Ltd. (Australia) IV-221
Pfizer Canada, Inc. (Canada) IV-222
Pfizer GmbH (Germany) IV-225
Pfizer Limited (UK) IV-226
32. Ranbaxy Pharmaceuticals, Inc. (USA) IV-229
33. Ratiopharm (Canada) IV-232
34. Recordati SpA (Italy) IV-233
Table 122: Half-Yearly Sales Analysis: 2004-2005 (H1)
(In € million) IV-234

Table 123: Annual Sales Analysis: 2003-2004 (In €
million) IV-235

Table 124: Annual Sales Analysis by Segment: 2003-2004
(In € million) IV-235

Table 125: Annual Sales Analysis by Geographical
Region: 2003-2004 (In € million) IV-235
35. Sankyo Pharma, Inc. (USA) IV-239
36. Sanofi-Aventis (France) IV-241
Table 126: Half Yearly Sales Analysis: 2004-2005 (H1)
(In € million) IV-242

Table 127: Half Yearly Sales Analysis by Segment: 2004
  • 2005 (H1) (In € million) IV-242
Table 128: Half Yearly Sales Analysis by Product: 2004
  • 2005 (H1) (In € million) IV-242
Table 129: Annual Sales Analysis: 2003-2004 (In US$
million) IV-243
37. Servier (France) IV-247
38. Skyepharma PLC (UK) IV-248
Table 130: Annual Sales Analysis: 2003-2004 (In £
million) IV-249

Table 131: Annual Sales Analysis by Region: 2003-2004
(In £ million) IV-249
39. Solvay SA (Belgium) IV-254
Table 132: First Quarter Sales Analysis: 2004-2005 (Q1)
(In € million) IV-255

Table 133: Annual Sales Analysis: 2003-2004 (In €
million) IV-255

Table 134: Annual Sales Analysis by Segment: 2003-2004
(In € million) IV-255
Solvay Pharmaceutical, Inc. (USA) IV-263
40. STADA Arzneimittel AG (Germany) IV-265
Table 135: First Quarter Sales Analysis: 2004-2005 (Q1)
(In € million) IV-265

Table 136: First Quarter Sales Analysis by Segment:
2004-2005 (Q1) (In € million) IV-266

Table 137: Annual Sales Analysis: 2003-2004 (In €
million) IV-266

Table 138: Annual Sales Analysis by Segment: 2003-2004
(In € million) IV-266
41. Strides Arcolab Limited (India) IV-268
42. Temmler Pharma GmbH & Co. KG (Germany) IV-271
43. Teva Pharmaceutical Industries Ltd. (Israel) IV-272
Table 139: Half Yearly Sales Analysis: 2004-2005 (H1)
(In US$ Million) IV-273
Table 140: Half Yearly Sales Analysis by Geographic
Region: 2004-2005 (H1) (In US$ Million) IV-273
Table 141: Half Yearly Sales Analysis by Business
Segment: 2004-2005 (H1) (In US$ Million) IV-274

Table 142: Annual Sales Analysis by Geographic Region:
2003-2004 (In US$ Million) IV-274

Table 143: Annual Sales Analysis by Business Segment:
2003-2004 (In US$ Million) IV-274
44. Watson Pharmaceuticals, Inc. (USA) IV-279
Table 144: Annual Sales Analysis: 2003-2004 (In US$
million) IV-280

Table 145: Annual Sales Analysis by Business Segment:
2003-2004 (In US$ million) IV-280
45. Wyeth (USA) IV-283
Table 146: Half yearly Sales Analysis: 2004-2005 (H1)
(In US$ million) IV-285

Table 147: Half Yearly Sales Analysis by Segment: 2004
  • 2005 (H1) (In US$ million) IV-285
Table 148: Annual Sales Analysis: 2003-2004 (In US$
million) IV-285

Table 149: Annual Sales Analysis by Segment: 2003-2004
(In US$ million) IV-285

Table 150: Annual Sales Analysis by Region: 2003-2004
(In US$ million) IV-285
Wyeth Australia Pty., Ltd. (Australia) IV-290
Wyeth Pharmaceuticals (USA) IV-292
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AstraZeneca Plc (UK)
  • Bristol-Myers Squibb (USA)
  • Eli Lilly and Co. (USA)
  • Forest Laboratories (USA)
  • GlaxoSmithKline Plc (UK)
  • H. Lundbeck A/S (Denmark)
  • Merck & Co. (USA)
  • Novartis AG (Switzerland)
  • Organon International, Inc. (USA)
  • Pfizer, Inc. (USA)
  • Solvay SA (Brussels)
  • Wyeth Pharmaceuticals (USA)
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/338526
Adroll
adroll